Skip to content

A clinical trial to evaluate the efficacy and safety of traditional Chinese medicine preventing relapse and metastasis of triple-negative breast cancer breast cancer

A clinical trial to evaluate the efficacy and safety of traditional Chinese medicine preventing relapse and metastasis of triple-negative breast cancer breast cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-16009861
Enrollment
Unknown
Registered
2016-11-14
Start date
2016-11-18
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

triple negative breast cancer

Interventions

Traditional Chinese medicine (TCM) exposed group:Western medicine standard treatment with traditional Chinese medicine therapy
Traditional Chinese medicine (TCM) nonexposed group:Western medicine standard treatment without Traditional Chinese medicine

Sponsors

Longhua Hospital Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Primary breast cancer after surgical treatment, by pathological examination diagnosis for breast malignant epithelial tumors (breast cancer)IHC: ER(-)PR(-), Her-2(-); 2. Into the group from pre-chemotherapy to the completion of chemotherapy period was not more than 3 months, confirmed no recurrence or metastasis of the tumor; 3. KPS score>=60; 4. Female patients aged 18~75 years the expeted survival >6 months; 5. No severe organic or functional diseases, drug and food allergies; 6. Willing to accept treatment, observation and the examinations.

Exclusion criteria

Exclusion criteria: 1. Do not meet the inclusion criteria; 2. Patients with obstruction can't take Chinese traditional medicine; 3. Pregnant and lactating women; 4. Allergic constitution, and a variety of drug allergy; 5. A serious disease of heart, liver, kidney and hematopoietic system and mental illness patients; 6. Patients were undergoing other drug test.

Design outcomes

Primary

MeasureTime frame
progression-free survival;overall survival;quality of life;

Countries

China

Contacts

Public ContactLiu Sheng

Longhua Hospital Shanghai University of Traditional Chinese Medicine

lshtcm@163.com+86 021-64385700

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026